(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...
FinanceBuzz on MSN
14 prescription drugs Medicare Part D won’t cover in 2026
Millions rely on Medicare Part D, but many prescription drugs won't be covered in 2026. See which meds are excluded, why, and ...
U.S. Humira sales fell 40% year over year during the first three months of 2024, to about $1.8 billion, as biosimilar copycats put pressure on AbbVie’s top-selling drug, the company said Friday in its ...
Humira is a type of immunosuppressant known as a tumor necrosis factor (TNF) inhibitor. It’s prescribed to treat autoimmune conditions. TNF is a protein that plays a key role in inflammation. In ...
Skyrizi (risankizumab-rzaa) and Humira (adalimumab) are prescription drugs that treat conditions such as psoriatic arthritis. The cost of both drugs depends on several factors. Skyrizi and Humira are ...
After falling just short of the $20 billion figure in annual sales for three straight years, AbbVie's Humira finally topped the elusive mark—and did it by a comfortable margin—generating $20.7 billion ...
You might call it the Swiss army knife of pharmaceutical drugs. Since it hit the market in 2002 to treat rheumatoid arthritis, Humira has racked up one governmental approval after another to treat ...
Another major pharmacy benefit manager is adding Humira biosimilars to its formulary beginning next year. Express Scripts, which is part of Cigna's Evernorth subsidiary, said Monday that it will add ...
FILE - Packaging for AbbVie's drug, Humira. Humira-referenced biosimilars have been launched this year, but have thus far gained very little traction. (AP Photo/David J. Phillip, File) The blockbuster ...
The pharmaceutical industry is known to defend its big prices for drugs by citing the risky nature of drug development and the regularly touted study showing it costs more than $2.5 billion to ...
California’s insurance regulator has accused pharmaceutical giant AbbVie of using kickbacks and other illegal practices to boost sales of Humira, one of the best-selling prescription drugs in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results